Intrexon Corporation, a synthetic biology company, has closed a $100m Series E financing round.
Investors include new shareholders, who committed the majority portion of the round and existing backers, including Randal J Kirk, Intrexon’s Chairman and CEO, and Third Security, LLC.
This investment brings the total amount raised by the company to date to over $259m.
Intrexon intends to use the funds for working capital for its commercial divisions and to expand its UltraVector® platform, which is designed to employ modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.
Founded in 1998, the company has facilities in Maryland, Virginia, North Carolina and California.